AOD-9604 is a synthetic fragment of human growth hormone (residues 176-191) promoted for fat loss without the wider effects of GH, though that mechanism is not well validated in people. Past human obesity trials missed their efficacy goals, and it remains unapproved and gray-market. Educational, not medical advice.
A synthetic fragment of human growth hormone (C-terminal 176-191) hypothesized to stimulate lipolysis without full systemic GH effects; mechanism in humans is not well validated.
Half-life
Uncertain; limited reliable human PK data. Treat as unknown.
Regulatory status
Not FDA-approved. Failed to show efficacy as an obesity drug in past human trials. Removed from FDA Category 2 in Sept 2024 after the nomination was withdrawn (this does not make it an approved drug). Gray-market/research use.
Safety
Reported as generally well tolerated in short studies, but real-world efficacy and long-term safety are not established.
Evidence
Some human trial data (obesity trials that did not meet efficacy goals); otherwise limited.
Track AOD-9604 in PepWise
Log every dose and injection site, get the reconstitution and units math automatically, follow your cycle, and record how you feel, then export a provider report. AOD-9604 tracker, free to start.
Sources
Heffernan MA, et al. Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese mice and beta(3)-AR knockout mice. Endocrinology. 2001;142(12):5182-9. https://pubmed.ncbi.nlm.nih.gov/11713213/
Heffernan MA, et al. Effects of human GH and its lipolytic fragment (hGH 177-191) on lipid metabolism. Int J Obes. 2001;25(10):1442-8. https://pubmed.ncbi.nlm.nih.gov/11673763/
Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. https://pubmed.ncbi.nlm.nih.gov/11146367/
Kwon DR, Park GY. Effect of Intra-articular AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-32. https://pubmed.ncbi.nlm.nih.gov/26275694/
Sakharova AA, et al. Role of growth hormone in regulating lipolysis, proteolysis, and hepatic glucose production during fasting. J Clin Endocrinol Metab. 2008;93(7):2755-9. https://pubmed.ncbi.nlm.nih.gov/18413425/
Surya S, et al. Pattern of GH delivery determines IGF-1 and lipolytic responses in obese subjects. J Clin Endocrinol Metab. 2009;94(8):2828-34. https://pubmed.ncbi.nlm.nih.gov/19470622/
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. AOD-9604 may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
